JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, J. A.
Right arrow Articles by Relling, M. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, J. A.
Right arrow Articles by Relling, M. V.

Vol. 294, Issue 3, 1099-1105, September 2000

CYP1A2 and CYP2D6 4-Hydroxylate Propranolol and Both Reactions Exhibit Racial Differences1

Julie A. Johnson2 , Vanessa L. Herring, Michael S. Wolfe3 and Mary V. Relling

College of Pharmacy, University of Tennessee, Memphis, Memphis, Tennessee (J.A.J., V.L.H., M.S.W.); and St. Jude Children's Research Hospital and University of Tennessee College of Pharmacy, Memphis, Tennessee (M.V.R.)

We have previously shown racial differences in propranolol kinetics, with the largest differences appearing to be in its 4-hydroxylation. The purpose of this study was to identify and confirm the cytochrome P450 enzymes (CYP) with propranolol 4-hydroxylase activity, describe their enzyme kinetics, and determine whether there were racial differences in their catalytic activity. Eleven human recombinant, expressed CYPs were screened, but only CYP1A2 and CYP2D6 possessed propranolol 4-hydroxylase activity. Subsequent studies were conducted in human liver microsomes, including correlation, inhibition, enzyme kinetics, and racial comparison studies. Significant correlations were noted between propranolol 4-hydroxylation and ethoxyresorufin-O-deethylation (marker of CYP1A2 activity), with marked improvement in the correlations when CYP2D6-mediated propranolol 4-hydroxylation was inhibited with quinidine. Inhibition studies showed that quinidine inhibited approximately 55% of propranolol 4-hydroxylation and furaphylline (CYP1A2-selective inhibitor) inhibited about 45% of propranolol 4-hydroxylation. Median (range) parameter estimates of (S)-4-hydroxypropranolol [(S)-HOP] formation were a Vmax value of 307 (165-2397) and 721 (84-1975) pmol/mg of protein/60 min for CYP1A2 and CYP2D6, respectively, and a Km value of 21.2 (8.9-77.5) and 8.5 (5.9-31.9) µM for CYP1A2 and CYP2D6, respectively. CYP1A2- and CYP2D6-mediated propranolol 4-hydroxylation was about 70 and 100% higher (P < .05 for both), respectively, in African-Americans compared with Caucasians. In summary, we found that both CYP1A2 and CYP2D6 catalyze formation of 4-hydroxypropranolol and that both enzymes exhibited racial differences in this reaction. The observed racial differences in drug metabolism may have relevance to drug efficacy, toxicity, or carcinogen activation for CYP1A2 or CYP2D6 substrates.


1 This work was supported by National Institutes of Health Grant GM54297, Cancer Center CORE Grant CA21765, and Grants N01-DK-9-2310 and CA51001; a Center of Excellence Grant from the State of Tennessee; and American Lebanese Syrian Associated Charities (ALSAC). This research was presented in part at the 100th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 18-20, 1999, San Antonio, TX.

2 Present address: University of Florida College of Pharmacy, Gainesville, FL.

3 Present address: Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.


0022-3565/00/2943-1099$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
A. Ohno, Y. Saito, N. Hanioka, H. Jinno, M. Saeki, M. Ando, S. Ozawa, and J.-i. Sawada
INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL
Drug Metab. Dispos., February 1, 2004; 32(2): 235 - 239.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
P. Lu, M. L. Schrag, D. E. Slaughter, C. E. Raab, M. Shou, and A. D. Rodrigues
MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR
Drug Metab. Dispos., November 1, 2003; 31(11): 1352 - 1360.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. A. Marcucci, R. E. Pearce, C. Crespi, D. T. Steimel, J. S. Leeder, and A. Gaedigk
Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine
Drug Metab. Dispos., May 1, 2002; 30(5): 595 - 601.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.